Although this result indicates that IL-6 inhibition might trigger inflammatory demyelination in the CNS, elevated levels of the soluble IL-6 receptor, an indirect marker for reduced IL-6 signaling, were found to be significantly correlated with a reduced risk of MS. Here, IL6 is linked to myeloid sarcoma.